Patents - stay tuned to the technology

Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Ether oxygen is part of the chain

Subclass of:

564 - Organic compounds -- part of the class 532-570 series

564000000 - ORGANIC COMPOUNDS (CLASS 532, SUBCLASS 1)

564001000 - AMINO NITROGEN CONTAINING (E.G., UREA, SULFONAMIDES, NITROSAMINES, OXYAMINES, ETC., AND SALTS THEREOF)

564305000 - Benzene ring containing

564336000 - Amino nitrogen attached to aryl ring or ring system by an acyclic carbon or chain

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
564346000 Ether oxygen is part of the chain 7
20130178653NOVEL PRECURSOR OF RADIOLABELLED CHOLINE ANALOG COMPOUNDS - The present invention describes intermediate(s), pre-cursor(s), for the preparation of radialabelled choline analogs to be used as radiotracers for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of diseases.07-11-2013
564347000 The ether oxygen is bonded directly to the aryl ring or ring system 6
20090203940Method for preparing 4-[2-(dimethylamino)ethoxy]benzylamine as itopride-hydrocloride salt mediate - The present invention relates to a novel method for preparing an itopride-hydrochloride mediate of the formula 1, which is useful for digestive tract activator, and more particularly, the present invention provides with a method for preparing 4-[2-(dimethylamino)ethoxy]benzylamine of the formula 1, an itopride-hydrochloride mediate, whereby being capable of manufacturing in a high yield and lowering cost through a simple purification and a selective reaction, and the method is harmless and safe to human and environment due to not generating toxic gas. And specially, a super-high pressure hydrogenation and a reduction reaction using a metal catalyst are not carried out, therefore, it is very safe method, and also special manufacturing equipments are not needed.08-13-2009
20100076225Polymorphs of atomoxetine hydrochloride - The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder.03-25-2010
20160107983AN IMPROVED PROCESS FOR THE PREPARATION OF 3-ARYLOXY-3-PHENYLPROPYLAMINE AND SALT THEREOF - The present invention relates to an industrially feasible and economically viable process for the preparation of 3-aryloxy-3-phenylpropylarnine and salt of formula I thereof.04-21-2016
564352000 The aryl ring or ring system is polycyclo 1
20140073814AMINOETHYLATION PROCESS HAVING IMPROVED YIELD OF ARYLOXYALKYLENE AMINE COMPOUNDS AND REDUCED UREA BY-PRODUCTS - Disclosed is a process for preparing an aryloxyalkylene amine compound via an aminoethylation reaction comprising: a) reacting an aromatic hydroxyl compound in the presence of a basic catalyst with a 2-oxazolidinone compound of the formula II to form an intermediate reaction product;03-13-2014
564353000 Hydrogen or acyclic hydrocarbyl substituents only bonded directly to the part of the chain between the ether oxygen and amino nitrogen 2
20090082597PROCESS FOR PREPARING A COMPOUND - The invention relates to the use of copper-catalyzed nucleophilic aromatic substitution reaction for preparing 3-aryloxy-3-arylpropylamines and more specifically to a method of preparing certain 3-aryloxy-3-arylpropylamines and the pharmaceutically acceptable addition salts thereof, comprising reacting an amino alcohol with a haloaromatic compound in the presence of a base and a catalytic copper source, and in the absence of a separate ligand.03-26-2009
20090156863ATOMOXETINE HYDROCHLORIDE PURE CRYSTALLINE FORM - The present invention discloses a process for the preparation of atomoxetine hydrochloride in a pure crystalline form, characterised by an XRPD spectrum as in FIG. 06-18-2009
Website © 2025 Advameg, Inc.